Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations
暂无分享,去创建一个
G. Kaplan | A. Griffiths | A. Bitton | C. Bernstein | J. Windsor | R. Panaccione | E. Benchimol | D. Gibson | L. Targownik | Jennifer L Jones | C. Seow | S. Murthy | J. Ghia | M. E. Kuenzig | P. Tandon | Kate Lee | James Guoxian Huang | Mariam S Mukhtar | J. Huang
[1] M. Diamond,et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses , 2021, Nature.
[2] N. Mahmud,et al. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications , 2021, Gastroenterology.
[3] H. Sørensen,et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study , 2021, BMJ.
[4] Elisabeth Mahase. Covid-19: Unusual blood clots are “very rare side effect” of Janssen vaccine, says EMA , 2021, BMJ.
[5] Andreas Greinacher,et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.
[6] J. Mascola,et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 , 2021, The New England journal of medicine.
[7] C. Lees,et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD , 2021, Gut.
[8] C. Lees,et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab , 2021, Gut.
[9] M. Hernán,et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.
[10] M. Hayney,et al. What Gastroenterologists Should Know About COVID-19 Vaccines , 2021, Clinical Gastroenterology and Hepatology.
[11] P. Moayyedi,et al. COVID-19 Vaccination in Patients With Inflammatory Bowel Disease: Communiqué From the Canadian Association of Gastroenterology , 2021, Journal of the Canadian Association of Gastroenterology.
[12] M. Parkes,et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement , 2021, The Lancet Gastroenterology & Hepatology.
[13] M. Dubinsky,et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting , 2021, Gut.
[14] M. Kappelman,et al. Reply , 2021, Gastroenterology.
[15] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[16] Elizabeth B White,et al. Diverse Functional Autoantibodies in Patients with COVID-19 , 2020, Nature.
[17] D. Lei,et al. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals , 2020, Nature Microbiology.
[18] V. Tagalakis,et al. Current estimates of the incidence of acute venous thromboembolic disease in Canada: A meta-analysis. , 2020, Thrombosis research.
[19] C. Aschwanden. The false promise of herd immunity for COVID-19 , 2020, Nature.
[20] F. Underwood,et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry , 2020, Gut.
[21] F. Krammer. SARS-CoV-2 vaccines in development , 2020, Nature.
[22] Kelsey K. Finn,et al. Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19 , 2020, Cell.
[23] R. Fouchier,et al. High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab , 2020, Vaccines.
[24] S. Ng,et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry , 2020, Gastroenterology.
[25] M. Merad,et al. Immunology of COVID-19: Current State of the Science , 2020, Immunity.
[26] J. Weinberg,et al. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy. , 2018, Inflammatory bowel diseases.
[27] A. Cheifetz,et al. Herpes Zoster Vaccine Response in Inflammatory Bowel Disease Patients on Low-dose Immunosuppression , 2016, Inflammatory bowel diseases.
[28] G. Kaplan,et al. Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial , 2016, Inflammatory bowel diseases.
[29] J. Walkowiak,et al. Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel Disease , 2015, Inflammatory bowel diseases.
[30] Eun Soo Kim,et al. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. , 2014, Journal of Crohn's & colitis.
[31] B. Feagan,et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results , 2014, Gut.
[32] K. Tominaga,et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. , 2014, Journal of Crohn's & colitis.
[33] Jin-Ho Kim,et al. Efficacy of Hepatitis A Vaccination and Factors Impacting on Seroconversion in Patients with Inflammatory Bowel Disease , 2014, Inflammatory bowel diseases.
[34] K. Papp,et al. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. , 2013, Journal of drugs in dermatology : JDD.
[35] L. Peyrin-Biroulet,et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study* , 2011, Inflammatory bowel diseases.
[36] J. Korzenik,et al. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease , 2011, Gut.
[37] S. Targan,et al. Immunosuppression Impairs Response to Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.
[38] A. Bousvaros,et al. Immune Response to Influenza Vaccine in Children With Inflammatory Bowel Disease , 2009, The American Journal of Gastroenterology.
[39] Louis J. Cohen,et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.